Search Results - "JR Carpenter"

Targeted Treatment of Schizophrenia Symptoms as They Manifest, or Continuous Treatment to Reduce the Risk of Psychosis Recurrence by Davidson, Michael, Carpenter, William T

“…Abstract Current pharmacological treatment of schizophrenia employs drugs that interfere with dopamine neurotransmission, aiming to suppress acute exacerbation…”
Get full text

Schizophrenia: A view of immediate future by Carpenter, William T.

Get full text

The schizophrenia syndrome, circa 2024: What we know and how that informs its nature by Tandon, Rajiv, Nasrallah, Henry, Akbarian, Schahram, Carpenter, William T., DeLisi, Lynn E., Gaebel, Wolfgang, Green, Michael F., Gur, Raquel E., Heckers, Stephan, Kane, John M., Malaspina, Dolores, Meyer-Lindenberg, Andreas, Murray, Robin, Owen, Michael, Smoller, Jordan W., Yassin, Walid, Keshavan, Matcheri

“…With new data about different aspects of schizophrenia being continually generated, it becomes necessary to periodically revisit exactly what we know. Along…”
Get full text

Negative Symptoms: A Brief Story and Advances in Spain by Carpenter Jr, William T.

Get full text

Another view of the history of antipsychotic drug discovery and development by Carpenter, W T, Davis, J M

“…Chlorpromazine initiated effective pharmacotherapy for schizophrenia 60 years ago. This discovery initiated or stimulated key developments in the field of…”
Get full text

Advances in schizophrenia by Thaker, Gunvant K, Carpenter, William T

“…Recent studies into the etiology of schizophrenia have yielded both promising leads and disappointing dead ends, indicating the multifactored and complex…”
Get full text

Revisiting the Diagnosis of Schizophrenia: Where have we been and Where are We Going? by Keller, William R., Fischer, Bernard A., Carpenter, Jr, William T.

“…SUMMARY Appropriate and reliable classification of mental illness is crucial for advancing the field of psychiatry as agreement on diagnosis has broad…”
Get full text

Criticism of the DSM-V risk syndrome: A rebuttal by Carpenter, William T.

“…Cognitive Neuropsychiatry Criticism of the DSM-V risk syndrome: A rebuttal…”
Get full text

C.18.03 Advances in therapeutic treatment of negative and cognitive symptoms of schizophrenia: comprehensive and long-term treatment by Carpenter Jr, W.

Get full text

Schizophrenia: Disease, Syndrome, or Dimensions? by CARPENTER JR, WILLIAM T.

“…Schizophrenia has the status of a clinical syndrome and may comprise a number of specific disease entities. This construct is similar to dementia, in which…”
Get full text

Optimistic Bias in the Perception of Personal Risk: Patterns in Schizophrenia by Prentice, Kristen J., Gold, James M., Carpenter, William T.

“…OBJECTIVE: Biases in the perception of personal vulnerability to risk could influence how individuals make decisions in many contexts. Schizophrenia patients,…”
Get full text

Randomized controlled trial of a gluten-free diet in patients with schizophrenia positive for antigliadin antibodies (AGA IgG): a pilot feasibility study by Kelly, Deanna L., Demyanovich, Haley K., Rodriguez, Katrina M., Ciháková, Daniela, Talor, Monica V., McMahon, Robert P., Richardson, Charles M., Vyas, Gopal, Adams, Heather A., August, Sharon M., Fasano, Alessio, Cascella, Nicola G., Feldman, Stephanie M., Liu, Fang, Sayer, MacKenzie A., Powell, Megan M., Wehring, Heidi J., Buchanan, Robert W., Gold, James M., Carpenter, William T., Eaton, William W.

“…Approximately one-third of people with schizophrenia have elevated levels of anti-gliadin antibodies of the immunoglobulin G type (AGA IgG) — a higher rate…”
Get full text

Abnormal Patterns of Regional Cerebral Blood Flow in Schizophrenia With Primary Negative Symptoms During an Effortful Auditory Recognition Task by Lahti, Adrienne C., Holcomb, Henry H., Medoff, Deborah R., Weiler, Martin A., Tamminga, Carol A., Carpenter, William T.

“…OBJECTIVE: Using functional brain imaging, the authors sought to replicate their earlier finding of low metabolism in the middle frontal and inferior parietal…”
Get full text

Adverse effects and laboratory parameters of high-dose olanzapine vs. clozapine in treatment-resistant schizophrenia by Kelly, Deanna L, Conley, Robert R, Richardson, Charles M, Tamminga, Carol A, Carpenter, Jr, William T

“…Patients with treatment-resistant schizophrenia pose a major challenge to caregivers since only clozapine is documented as having superior efficacy in this…”
Get more information

Evidence-Based Treatment for First-Episode Schizophrenia? by CARPENTER, WILLIAM T.

“…Carpenter discusses a new study that adds important descriptive data to the three clinical trials addressing evidence-based treatment following an initial…”
Get full text

The Challenge to Psychiatry as Society's Agent for Mental Illness Treatment and Research by Carpenter, Jr, W T

“…Psychiatry faces an enormous challenge as society's agent for mental illness treatment and research. Carpenter discusses ways psychiatrists can meet the…”
Get full text

The RDoC Controversy: Alternate Paradigm or Dominant Paradigm? by Carpenter, William T.

Get full text

Deconstructing negative symptoms of schizophrenia: Avolition–apathy and diminished expression clusters predict clinical presentation and functional outcome by Strauss, Gregory P, Horan, William P, Kirkpatrick, Brian, Fischer, Bernard A, Keller, William R, Miski, Pinar, Buchanan, Robert W, Green, Michael F, Carpenter, William T

“…Abstract Background Previous studies indicate that negative symptoms reflect a separable domain of pathology from other symptoms of schizophrenia. However, it…”
Get full text

Prognosis of Brief Psychotic Episodes: A Meta-analysis by Fusar-Poli, Paolo, Cappucciati, Marco, Bonoldi, Ilaria, Hui, L M Christy, Rutigliano, Grazia, Stahl, Daniel R, Borgwardt, Stefan, Politi, Pierluigi, Mishara, Aaron L, Lawrie, Stephen M, Carpenter, Jr, William T, McGuire, Philip K

“…The prognostic significance of competing constructs and operationalizations for brief psychotic episodes (acute and transient psychotic disorder [ATPD], brief…”
Get more information

Comparative Effectiveness of Fluphenazine Decanoate Injections Every 2 Weeks Versus Every 6 Weeks by Carpenter, Jr, William T., Buchanan, Robert W., Kirkpatrick, Brian, Lann, Helen D., Breier, Alan F., Summerfelt, Ann T.

“…OBJECTIVE: Dose reduction strategies for the maintenance treatment of schizophrenia are designed to maintain the benefits of antipsychotic drug therapy while…”
Get full text